Explore

Rapid Read Rapid Read
Cooper University Health and MD Anderson Receive $100M Donation for Expansion

Cooper University Health and MD Anderson Receive $100M Donation for Expansion

Cooper University Health and its partner, MD Anderson Cancer Center, have received a $100 million donation to support their ongoing expansion efforts. This significant gift will aid in the $3 billion expansion project at Cooper's main campus in Camden, New Jersey. The expansion aims to enhance the facilities and services offered by the health system, which is a key provider of cancer care in the region. The donation is expected to accelerate the development of new infrastructure and technology, improving patient care and expanding access to advanced medical treatments.
Rapid Read Rapid Read
Curebound Expands Leadership Team to Accelerate Cancer Research Initiatives

Curebound Expands Leadership Team to Accelerate Cancer Research Initiatives

Curebound, a cancer research accelerator based in San Diego, has announced the appointment of three key executives to its leadership team. Mary Meyer has been named Chief Advancement Officer, Scotty Cadet, Ph.D., as Chief Scientific Officer and Vice President of Research, and Leena Gupta as Chief Financial Officer. These appointments aim to enhance Curebound's mission of funding innovative cancer research, focusing on early detection and personalized therapies. Meyer brings extensive experience in philanthropy, having led significant fundraising campaigns at Scripps Health. Cadet, with a background in drug discovery and clinical development, will lead Curebound's internal research and advisory board. Gupta, a seasoned finance leader, will oversee the organization's financial strategy to support its growing research initiatives.
Rapid Read Rapid Read
New Cancer Vaccine Platform Utilizes COVID-19 Immune Memory for Tumor Treatment

New Cancer Vaccine Platform Utilizes COVID-19 Immune Memory for Tumor Treatment

Researchers have developed a novel cancer vaccine platform, PROTEXI, which leverages pre-existing COVID-19 immune memory to enhance the body's ability to fight tumors. This dendritic cell vaccine uses the immune memory generated by SARS-CoV-2 infection or vaccination to stimulate a robust antitumor response. The platform pairs tumor-specific antigens with helper signals from the SARS-CoV-2 Spike protein, converting dormant antiviral memory into an active response against cancer cells. Preclinical studies have shown promising results, with the vaccine reducing tumor burden and improving survival rates in melanoma and breast cancer models.
Rapid Read Rapid Read
New Human Tissue Model Advances Glioblastoma Research

New Human Tissue Model Advances Glioblastoma Research

Researchers at the University Hospital Bonn and the University of Bonn have developed a new model, Core2Edge, to study glioblastoma, an aggressive brain tumor. This model, based entirely on human tissue, captures the infiltration zones at the tumor margin, allowing for the investigation of invasive tumor cells and the assessment of new drug candidates without animal testing. Glioblastoma is known for its invasive behavior, with tumor cells migrating into healthy brain tissue, making it difficult to completely remove and leading to recurrence. The Core2Edge model combines glioblastoma organoids with human brain tissue, enabling researchers to track tumor spread and study the genetic activity of individual tumor cells.
Trendline Trendline
CORE Biomedicine Secures $21 Million to Advance Cancer Therapeutics

CORE Biomedicine Secures $21 Million to Advance Cancer Therapeutics

CORE Biomedicine Secures $21 Million to Advance Cancer Therapeutics
Rapid Read Rapid Read
EIOC 2026 Invites Oncology Researchers for Global Presentations

EIOC 2026 Invites Oncology Researchers for Global Presentations

The Excellence in Oncology Care (EIOC) has announced the opening of abstract submissions for its 2026 presentations. Researchers, oncologists, clinicians, and trainees are encouraged to submit their work for Oral and E-Poster presentations. Successful submissions will be eligible for a USD 1,000 Educational Grant. The deadline for submissions is August 31, 2026. This initiative aims to provide a global platform for innovative oncology research, encouraging the sharing of ideas that can advance cancer care.
Rapid Read Rapid Read
Technical University of Denmark Utilizes Quantum Computing to Enhance AI in Cancer Vaccine Design

Technical University of Denmark Utilizes Quantum Computing to Enhance AI in Cancer Vaccine Design

Researchers at the Technical University of Denmark have employed a photonic quantum computer to improve AI models in designing peptides, which are crucial for the immune system to recognize diseased or infected cells. This study, which is still awaiting peer review, demonstrated that AI-designed peptides could successfully bind to human leukocyte antigen (HLA) molecules, a critical step in triggering an immune response. The use of quantum computing introduces a new kind of randomness that aids AI in exploring a broader range of peptide designs, particularly for less-studied immune types. This approach could eventually lead to more personalized cancer vaccines and immune-based therapies.
Rapid Read Rapid Read
CRISPR Technology Enhances Prostate Cancer Immunotherapy Effectiveness

CRISPR Technology Enhances Prostate Cancer Immunotherapy Effectiveness

Researchers have developed a CRISPR-based RNA targeting technology that makes prostate cancer cells more susceptible to immunotherapy. Prostate tumors are typically 'immune cold,' attracting few T cells, which are crucial for immunotherapy to work. The new technology alters RNA within cancer cells, making them more visible to immune cells. This approach has shown improved responses in mice, with more immune cells infiltrating and attacking the tumors. The study, published in Nature Biomedical Engineering, highlights the potential of this method to enhance existing immunotherapies for prostate and other immune-cold tumors.
Rapid Read Rapid Read
UC San Diego Develops Fingertip Sweat Patch for Parkinson's Medication Monitoring

UC San Diego Develops Fingertip Sweat Patch for Parkinson's Medication Monitoring

Engineers and neuroscientists at the University of California, San Diego, have developed a wearable fingertip patch that monitors levodopa levels in Parkinson's disease patients by analyzing sweat. This innovative device, which requires no batteries, provides real-time data comparable to standard blood tests. The patch could enable personalized medication schedules, improving treatment precision. The research, led by Tamoghna Saha and published in PNAS, highlights the potential for a closed-loop system where the patch communicates with a drug delivery pump, optimizing therapeutic outcomes for Parkinson's patients.
Rapid Read Rapid Read
Gene Editing Enhances Immune Response to Prostate Cancer in Preclinical Study

Gene Editing Enhances Immune Response to Prostate Cancer in Preclinical Study

Researchers from Duke University and the University of Rochester have developed a gene-editing technology that could significantly improve the effectiveness of immunotherapy for prostate cancer. The study, published in Nature Biomedical Engineering, utilized CRISPR technology to modify the way prostate cancer cells process messenger RNA (mRNA). This alteration made the tumors more visible to the immune system, allowing for a more robust immune response. In preclinical trials with mice, the treatment increased the infiltration of immune cells into tumors, enhancing the efficacy of immune checkpoint therapy. The research builds on previous findings that certain cancers evade immune detection by shortening mRNA molecules, which affects protein production and immune recognition.
Rapid Read Rapid Read
University of Vermont Researchers Identify New Treatment Strategy for Mesothelioma

University of Vermont Researchers Identify New Treatment Strategy for Mesothelioma

Researchers at the University of Vermont, in collaboration with RS Oncology, have discovered a promising new treatment strategy for mesothelioma, a rare and aggressive cancer. The study, published in Nature Communications, reveals that blocking the enzyme peroxiredoxin 3 (PRX3) in cancer cells can lead to their death. This approach contrasts with previous methods that aimed to protect cancer cells from oxidative damage. The research team, led by Victoria Gibson and Brian Cunniff, found that inhibiting PRX3 causes harmful molecules to accumulate in cancer cells, ultimately leading to cell death. A phase one clinical trial showed that the experimental drug stopped disease progression in 67% of patients with relapsed mesothelioma. The treatment was well tolerated, and patients survived longer than those receiving standard therapies.
Rapid Read Rapid Read
mRNA Vaccines Show Promise in Cancer Treatment Amidst Infrastructure Challenges

mRNA Vaccines Show Promise in Cancer Treatment Amidst Infrastructure Challenges

mRNA vaccines are being explored as a promising treatment for cancer, particularly in pancreatic cancer, where they are combined with neoadjuvant chemotherapy to target remaining cancer cells. Early-phase clinical trials have shown that personalized mRNA cancer vaccines can generate durable immune responses and antitumor activity. However, the implementation of these vaccines faces significant infrastructure challenges, including high production costs and complex logistics. Personalized vaccines can cost over $100,000 per patient to produce, requiring specialized manufacturing facilities and a sophisticated logistics network. Despite these challenges, mRNA vaccines have been well tolerated in trials, with manageable toxicities and no evidence of insertional mutagenesis.